Literature DB >> 20570885

One year recurrence of aberrant crypt foci.

Paul F Pinsky1, James Fleshman, Matt Mutch, Christopher Rall, Aline Charabaty, David Seligson, Sarah Dry, Asad Umar, Robert E Schoen.   

Abstract

Aberrant crypt foci (ACF) are putative precursors of colorectal adenomas and have been postulated as a potential biomarker for colorectal cancer. Few studies have followed subjects after ACF removal to monitor recurrence. Subjects enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were recruited for a study of ACF. A standardized protocol using magnified endoscopy and mucosal staining with methylene blue was implemented to detect rectal ACF. After removal of all baseline ACF, subjects returned 1 year later and recurrent ACF were observed and biopsied. A total of 434 of 505 (86%) subjects observed at baseline returned for the year 1 exam. The mean number of ACF at year 1 was strongly correlated with the number at baseline; subjects with 0, 1, 2 to 3, 4 to 6, and 7+ ACF at baseline had a mean of 1.2, 1.4, 1.7, 3.0, and 5.5 ACF, respectively, at year 1. ACF prevalence and mean count at year 1 (61% and 1.93, respectively), were only slightly lower than the corresponding values at year 0 (69% and 2.25, respectively). The locations of ACF at year 1 and baseline were significantly correlated. Of 96 ACF assessed for histology, 70 (73%) were hyperplastic and none were dysplastic. After removal of ACF at baseline, ACF counts 1 year later were only slightly reduced and were significantly correlated with the baseline ACF count. The results of this study do not support a role for ACF in clinical practice. 2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20570885      PMCID: PMC2900400          DOI: 10.1158/1940-6207.CAPR-09-0257

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  15 in total

1.  Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population.

Authors:  Darran Moxon; Mamoon Raza; Richard Kenney; Ronald Ewing; Ahsan Arozullah; Joel B Mason; Robert E Carroll
Journal:  Clin Gastroenterol Hepatol       Date:  2005-03       Impact factor: 11.382

Review 2.  Role of aberrant crypt foci detected using high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis.

Authors:  David P Hurlstone; Simon S Cross
Journal:  J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 4.029

3.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Authors:  P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan
Journal:  Control Clin Trials       Date:  2000-12

Review 4.  Aberrant crypt foci: what we know and what we need to know.

Authors:  Akshay K Gupta; Theresa P Pretlow; Robert E Schoen
Journal:  Clin Gastroenterol Hepatol       Date:  2007-04-12       Impact factor: 11.382

5.  Aberrant crypt foci of the colon as precursors of adenoma and cancer.

Authors:  T Takayama; S Katsuki; Y Takahashi; M Ohi; S Nojiri; S Sakamaki; J Kato; K Kogawa; H Miyake; Y Niitsu
Journal:  N Engl J Med       Date:  1998-10-29       Impact factor: 91.245

6.  The yield of surveillance colonoscopy by adenoma history and time to examination.

Authors:  Paul F Pinsky; Robert E Schoen; Joel L Weissfeld; Timothy Church; Lance A Yokochi; V Paul Doria-Rose; Philip Prorok
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07-26       Impact factor: 11.382

7.  Reliability and accuracy of the endoscopic appearance in the identification of aberrant crypt foci.

Authors:  Akshay K Gupta; Paul Pinsky; Christopher Rall; Matthew Mutch; Sarah Dry; David Seligson; Robert E Schoen
Journal:  Gastrointest Endosc       Date:  2009-06-21       Impact factor: 9.427

8.  National Polyp Study data: evidence for regression of adenomas.

Authors:  Franka Loeve; Rob Boer; Ann G Zauber; Marjolein Van Ballegooijen; Gerrit J Van Oortmarssen; Sidney J Winawer; J Dik F Habbema
Journal:  Int J Cancer       Date:  2004-09-10       Impact factor: 7.396

9.  The natural history of aberrant crypt foci.

Authors:  Robert E Schoen; Matthew Mutch; Christopher Rall; Sarah M Dry; David Seligson; Asad Umar; Paul Pinsky
Journal:  Gastrointest Endosc       Date:  2008-02-21       Impact factor: 9.427

10.  Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup.

Authors:  S J Winawer; A G Zauber; M J O'Brien; M N Ho; L Gottlieb; S S Sternberg; J D Waye; J Bond; M Schapiro; E T Stewart
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

View more
  6 in total

1.  Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.

Authors:  Paul J Limburg; Michelle R Mahoney; Katie L Allen Ziegler; Stephen J Sontag; Robert E Schoen; Richard Benya; Michael J Lawson; David S Weinberg; Elena Stoffel; Michael Chiorean; Russell Heigh; Joel Levine; Gary Della'Zanna; Luz Rodriguez; Ellen Richmond; Christopher Gostout; Sumithra J Mandrekar; Thomas C Smyrk
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-05

2.  Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.

Authors:  Hemant K Roy; Vladimir Turzhitsky; Ramesh Wali; Andrew J Radosevich; Borko Jovanovic; Gary Della'Zanna; Asad Umar; David T Rubin; Michael J Goldberg; Laura Bianchi; Mart De La Cruz; Andrej Bogojevic; Irene B Helenowski; Luz Rodriguez; Robert Chatterton; Silvia Skripkauskas; Katherine Page; Christopher R Weber; Xiaoke Huang; Ellen Richmond; Raymond C Bergan; Vadim Backman
Journal:  Gut       Date:  2015-10-26       Impact factor: 23.059

Review 3.  State of the art in advanced endoscopic imaging for the detection and evaluation of dysplasia and early cancer of the gastrointestinal tract.

Authors:  Sergio Coda; Andrew V Thillainayagam
Journal:  Clin Exp Gastroenterol       Date:  2014-05-13

4.  Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk.

Authors:  Isabel Quintanilla; María López-Cerón; Mireya Jimeno; Miriam Cuatrecasas; Michel Zabalza; Leticia Moreira; Virginia Alonso; Cristina Rodríguez de Miguel; Jennifer Muñoz; Sergi Castellvi-Bel; Josep Llach; Antoni Castells; Francesc Balaguer; Jordi Camps; Maria Pellisé
Journal:  Clin Transl Gastroenterol       Date:  2019-06       Impact factor: 4.488

5.  Risk factors for colorectal cancer in man induce aberrant crypt foci in rats: Preliminary findings.

Authors:  Kai Yang; Sara Fard; Rudolf Furrer; Michael C Archer; W Robert Bruce; HoYin Lip; Rhea Mehta; Peter J O'Brien; Adria Giacca; Wendy E Ward; A Pietro Femia; Giovanna Caderni; Alan Medline; Kate Banks
Journal:  Nutr Cancer       Date:  2015-12-28       Impact factor: 2.900

6.  Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.

Authors:  Ramesh K Wali; Laura Bianchi; Sonia Kupfer; Mart De La Cruz; Borko Jovanovic; Christopher Weber; Michael J Goldberg; L M Rodriguez; Raymond Bergan; David Rubin; Mary Beth Tull; Ellen Richmond; Beth Parker; Seema Khan; Hemant K Roy
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.